Core Viewpoint - The company, Innovent Biologics (02121), has repurchased a total of 570,100 shares in the open market for a total consideration of HKD 4.3055 million, reflecting confidence in its business outlook and future prospects [1] Summary by Sections - Share Buyback Details - The company repurchased 570,100 shares in October 2025 [1] - The total cost of the share buyback was HKD 4.3055 million [1] - Board's Perspective - The board believes that the share buyback demonstrates confidence in the company's business outlook and future prospects [1] - The board anticipates that the buyback will ultimately benefit the company and create value for shareholders [1] - The company has sufficient financial resources to support the buyback while maintaining a robust financial position [1]
创新奇智10月共斥资430.55万港元回购57.01万股股份